Fluconazole IV

Fluconazole IV

Form: Intravenous (IV) Infusion

Strength: 200 mg/100 mL, 400 mg/200 mL

Reference Brands: Diflucan IV(US & EU)

Category: Critical Care

Fluconazole IV is a widely used antifungal agent for treating systemic and severe fungal infections, including candidemia and cryptococcal meningitis, especially in immunocompromised patients. Available in IV infusion formats such as 200 mg/100 mL and 400 mg/200 mL premixed bags, and in vials for reconstitution (100 mg–400 mg), Fluconazole ensures effective hospital-based therapy. In the US, it is sold under the brand Diflucan IV by Pfizer, with multiple generics from Fresenius, Hikma, and Sagent. In the EU, brands include Fluconazole by Mylan, Accord, and Sandoz. Pharma B2B platforms facilitate reliable sourcing of Fluconazole IV for critical hospital needs.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Glucagon

Strength: 1 mg lyophilized powder for reconstitution (IM/SC/IV)

Form: Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) injection

Reference Brands: Glucagen®, Gvoke®,Baqsimi®(US); Glucagen® Hypokit(EU)

View Details Get Enquiry
Insulin (IV)

Strength: 100 units/mL (U-100) in 10 mL vials

Form: Intravenous (IV) solution

Reference Brands: Humulin® R, Novolin® R(US); Actrapid®, Humulin® R, Insuman® Rapid(EU)

View Details Get Enquiry
Flumazenil

Strength: 0.1 mg/mL in 5 mL or 10 mL vials

Form: Intravenous (IV) injection

Reference Brands: Romazicon®(US), Anexate®(EU)

View Details Get Enquiry
Naloxone

Strength: 0.4 mg/mL in 1 mL/10 mL vials, 1 mg/mL in 2 mL prefilled syringes

Form: Intravenous (IV) injection/IM/SQ

Reference Brands: Narcan® (US); Narcan® (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.